WU-SN-TMC Biospecimen Core

生物样本核心摘要/摘要 衰老是一种复杂的表型，可能由许多与人类有关的状态组成 健康和疾病。我们的目标是创建华盛顿大学衰老组织图谱中心（WU- SN-TMC），它将利用我们广泛的基础设施来生成多组学和成像数据来构建 跨组织类型和寿命的细胞衰老的高分辨率、多维图谱，可以 用于实现基础和转化衰老研究。我们的 WU-SN-TMC 将开发蜂窝 使用 500 个人体样本绘制四种基本组织类型的衰老图谱：骨髓、乳腺、结肠、 和肝脏。为了实现这一雄心勃勃的目标，WU-SN-TMC 生物样本核心 (WU-SN-TMC BC) 已 旨在促进不同年龄段人体组织的收集。此外，WU-SN- TMC BC 将从个人身上收集多个组织，以便我们比较衰老数量和状态 来自单个个体的跨组织。 WU-SN-TMC BC 将通过使用样本来实现这一目标 采集管道分为四个利用 WU 的组织前瞻性采集协议 (CP) 收集相关生物样本的临床专业知识和患者数量。这些 CP 包括： 1) CP1，它将 从各年龄段无慢性病的正常捐献者身上采集骨髓； 2）CP2，包括正常 来自不同年龄段接受乳房美容手术的患者的乳房、骨髓和皮肤； 3）CP3，其中 包括接受内窥镜检查的患者，这些患者将提供正常的胃、小肠和结肠 年龄； 4) CP4 包括接受腹腔镜上消化道手术的患者，该手术将提供 正常的骨髓、肝脏和皮肤，同样跨越年龄。虽然我们的重点是人类的衰老 随着年龄的增长，CP2 和 CP4 中的一些患者将接受先前针对无关组织癌症的化疗 （即生物样本将来自未受影响的、无癌症的组织）。该队列将提供机会 比较年龄匹配的对照/-化疗并允许在生物实验中的小鼠中进行扰动测试 分析核心（BAC）将映射回人体组织以获得相关性，进一步丰富骨髓， 我们将制作乳房、结肠和肝脏图谱。西弗吉尼亚大学现有的基础设施、我们的患者数量以及 我们团队的专业知识将确保 WU-SN-TMC BC 的成功。

Biospecimen Core Summary/Abstract Senescence is a complex phenotype that likely consists of many states that have been implicated in human health and disease. We aim to create the Washington University Senescence Tissue Mapping Center (WU- SN-TMC), which will leverage our expansive infrastructure to generate multi-omics and imaging data to build high resolution, multi-dimensional atlases of cellular senescence across tissue types and lifespan that can be used to enable basic and translational senescence research. Our WU-SN-TMC will develop cellular senescence atlases using 500 human samples for four essential tissue types: bone marrow, breast, colon, and liver. To tackle such an ambitious goal, the WU-SN-TMC Biospecimen Core (WU-SN-TMC BC) has been designed to facilitate the collection of human tissues across a wide range of ages. In addition, the WU-SN- TMC BC will collect multiple tissues from individuals to allow us to compare senescent numbers and states across tissues from a single individual. The WU-SN-TMC BC will accomplish this goal by using sample acquisition pipelines that are divided into four tissue prospective collection protocols (CPs) that leverage WU clinical expertise and patient volume to collect relevant biospecimens. These CPs include: 1) CP1, which will collect bone marrow from normal donors without chronic disease across ages; 2) CP2, which includes normal breast, bone marrow and skin from patients undergoing cosmetic breast surgery across ages; 3) CP3, which includes patients undergoing endoscopy who will provide normal stomach, small bowel, and colon across ages; and 4) CP4 includes patients undergoing laparoscopic upper gastrointestinal surgery that will provide normal bone marrow, liver, and skin, again across ages. While our focus is on senescence during human aging, some patients in CP2 and CP4 will have received prior chemotherapy for cancers in unrelated tissues (i.e. biospecimens will be from unaffected, cancer-free tissues). This cohort will provide the opportunity to compare age-matched controls +/- chemotherapy and allow perturbations tested in mice in the Biological Analysis Core (BAC) to be mapped back to human tissue for relevance, further enriching the bone marrow, breast, colon, and liver atlases we will produce. The existing infrastructure at WU, our patient volume and the expertise of our team will ensure the success of the WU-SN-TMC BC.